Etoposide
Etopophos, Toposar, Vepesid (etoposide) is a small molecule pharmaceutical. Etoposide was first approved as Vepesid on 1983-11-10. It is used to treat brain neoplasms, ewing sarcoma, histiocytosis, kaposi sarcoma, and lung neoplasms amongst others in the USA. The pharmaceutical is active against DNA topoisomerase 2-alpha. In addition, it is known to target DNA topoisomerase 2-beta.
Download report
Favorite
BMS
Commercial
Trade Name
FDA
EMA
Etopophos (generic drugs available since 1995-07-17, discontinued: Toposar, Vepesid)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Etoposide
Etoposide phosphate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ETOPOPHOS PRESERVATIVE FREE | CHEPLAPHARM Arzneimittel | N-020457 RX | 1996-05-17 | 1 products, RLD, RS |
Show 1 discontinued
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| brain neoplasms | EFO_0003833 | D001932 | C71 |
| ewing sarcoma | EFO_0000173 | D012512 | — |
| histiocytosis | HP_0100727 | D015614 | — |
| kaposi sarcoma | — | D012514 | C46 |
| lung neoplasms | — | D008175 | C34.90 |
| mycosis fungoides | — | D009182 | C84.0 |
| myeloid leukemia acute | — | D015470 | C92.0 |
| neuroblastoma | EFO_0000621 | D009447 | — |
| prostatic neoplasms | — | D011471 | C61 |
| rhabdomyosarcoma | — | D012208 | — |
Show 4 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
Clinical
Clinical Trials
1301 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Small cell lung carcinoma | D055752 | 28 | 55 | 30 | 1 | — | 98 | ||
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | C91.0 | 18 | 44 | 26 | 8 | 5 | 87 | |
| Non-hodgkin lymphoma | D008228 | C85.9 | 24 | 57 | 4 | 1 | 4 | 77 | |
| Myeloid leukemia acute | D015470 | C92.0 | 30 | 35 | 18 | 1 | 2 | 73 | |
| Large b-cell lymphoma diffuse | D016403 | C83.3 | 31 | 42 | 12 | 1 | 3 | 73 | |
| Burkitt lymphoma | D002051 | C83.7 | 12 | 13 | 1 | 2 | 3 | 27 | |
| Mantle-cell lymphoma | D020522 | C83.1 | 12 | 15 | 1 | 1 | 3 | 24 | |
| Germ cell and embryonal neoplasms | D009373 | 3 | 11 | 6 | 1 | 3 | 23 | ||
| T-cell lymphoma peripheral | D016411 | C84.9 | 9 | 10 | — | 1 | 3 | 21 | |
| Large-cell lymphoma anaplastic | D017728 | C84.6 | 7 | 11 | — | 2 | 3 | 19 |
Show 6 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoma | D008223 | C85.9 | 28 | 133 | 36 | — | 9 | 193 | |
| Leukemia | D007938 | C95 | 28 | 64 | 37 | — | 3 | 119 | |
| Lung neoplasms | D008175 | C34.90 | 20 | 46 | 24 | — | — | 80 | |
| Neuroblastoma | D009447 | EFO_0000621 | 15 | 28 | 18 | — | 5 | 63 | |
| Hodgkin disease | D006689 | C81 | 19 | 37 | 10 | — | 3 | 55 | |
| Neoplasms | D009369 | C80 | 33 | 18 | 4 | — | 2 | 50 | |
| Non-small-cell lung carcinoma | D002289 | 14 | 26 | 11 | — | 1 | 46 | ||
| Myelodysplastic syndromes | D009190 | D46 | 17 | 18 | 11 | — | 1 | 43 | |
| Sarcoma | D012509 | 8 | 18 | 12 | — | 2 | 39 | ||
| Central nervous system neoplasms | D016543 | 8 | 21 | 6 | — | 4 | 38 |
Show 70 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Plasma cell neoplasms | D054219 | 6 | 12 | — | — | 2 | 20 | ||
| B-cell chronic lymphocytic leukemia | D015451 | C91.1 | 6 | 11 | — | — | 3 | 17 | |
| Waldenstrom macroglobulinemia | D008258 | C88.0 | 4 | 5 | — | — | 3 | 10 | |
| Glioblastoma | D005909 | EFO_0000515 | 3 | 6 | — | — | — | 9 | |
| Graft vs host disease | D006086 | D89.81 | 2 | 4 | — | — | 3 | 9 | |
| B-cell lymphoma marginal zone | D018442 | C88.4 | 3 | 4 | — | — | 3 | 8 | |
| Lymphomatoid granulomatosis | D008230 | C83.8 | 4 | 3 | — | — | 3 | 8 | |
| Adult t-cell leukemia-lymphoma | D015459 | C91.5 | 3 | 3 | — | — | 2 | 7 | |
| Primitive neuroectodermal tumors | D018242 | 2 | 2 | — | — | 3 | 7 | ||
| Hairy cell leukemia | D007943 | C91.4 | 4 | 1 | — | — | 2 | 6 |
Show 76 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Large granular lymphocytic leukemia | D054066 | 2 | — | — | — | 2 | 4 | ||
| Neuroepithelial neoplasms | D018302 | 1 | — | — | — | — | 1 | ||
| Mycosis fungoides | D009182 | C84.0 | 1 | — | — | — | — | 1 | |
| Urologic neoplasms | D014571 | C64-C68 | 1 | — | — | — | — | 1 | |
| Urethral neoplasms | D014523 | EFO_0003846 | 1 | — | — | — | — | 1 | |
| Pancreatic ductal carcinoma | D021441 | 1 | — | — | — | — | 1 | ||
| Esophageal squamous cell carcinoma | D000077277 | 1 | — | — | — | — | 1 | ||
| Peritoneal neoplasms | D010534 | 1 | — | — | — | — | 1 | ||
| Pinealoma | D010871 | 1 | — | — | — | — | 1 | ||
| Deltaretrovirus infections | D006800 | EFO_1001303 | 1 | — | — | — | — | 1 |
Show 13 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chediak-higashi syndrome | D002609 | Orphanet_167 | D72.0 | — | — | — | — | 2 | 2 |
| Drug-related side effects and adverse reactions | D064420 | T88.7 | — | — | — | — | 1 | 1 | |
| Ataxia telangiectasia | D001260 | Orphanet_100 | G11.3 | — | — | — | — | 1 | 1 |
| Wiskott-aldrich syndrome | D014923 | D82.0 | — | — | — | — | 1 | 1 | |
| Severe combined immunodeficiency | D016511 | D81.0 | — | — | — | — | 1 | 1 | |
| Chronic granulomatous disease | D006105 | EFO_0000338 | D71 | — | — | — | — | 1 | 1 |
| Immunologic deficiency syndromes | D007153 | HP_0002721 | D84.9 | — | — | — | — | 1 | 1 |
| Type 1 hyper-igm immunodeficiency syndrome | D053307 | — | — | — | — | 1 | 1 | ||
| Common variable immunodeficiency | D017074 | EFO_0000367 | D83 | — | — | — | — | 1 | 1 |
| Leukocyte-adhesion deficiency syndrome | D018370 | EFO_1001359 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | ETOPOSIDE |
| INN | etoposide |
| Description | Etoposide is a beta-D-glucoside, a furonaphthodioxole and an organic heterotetracyclic compound. It has a role as an antineoplastic agent and a DNA synthesis inhibitor. It is functionally related to a podophyllotoxin and a 4'-demethylepipodophyllotoxin. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O |
Identifiers
| PDB | 3QX3 |
| CAS-ID | 33419-42-0 |
| RxCUI | 4179 |
| ChEMBL ID | CHEMBL44657 |
| ChEBI ID | 4911 |
| PubChem CID | 36462 |
| DrugBank | DB00773 |
| UNII ID | 6PLQ3CP4P3 (ChemIDplus, GSRS) |
Target
Agency Approved
TOP2A
TOP2A
Organism
Homo sapiens
Gene name
TOP2A
Gene synonyms
TOP2
NCBI Gene ID
Protein name
DNA topoisomerase 2-alpha
Protein synonyms
DNA gyrase, DNA topoisomerase (ATP-hydrolyzing), DNA topoisomerase II, 170 kD, DNA topoisomerase II, alpha isozyme, topoisomerase (DNA) II alpha 170kDa
Uniprot ID
Mouse ortholog
Top2a (21973)
DNA topoisomerase 2-alpha (Q01320)
Alternate
TOP2B
TOP2B
Organism
Homo sapiens
Gene name
TOP2B
Gene synonyms
NCBI Gene ID
Protein name
DNA topoisomerase 2-beta
Protein synonyms
antigen MLAA-44, DNA topoisomerase II, 180 kD, DNA topoisomerase II, beta isozyme, topo II beta, topoisomerase (DNA) II beta 180kDa, topoisomerase II beta, topoisomerase IIb, U937 associated antigen
Uniprot ID
Mouse ortholog
Top2b (21974)
DNA topoisomerase 2-beta (Q7TQG4)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 60,778 documents
View more details
Safety
Black-box Warning
Black-box warning for: Toposar
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
142,426 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more